AKT1 and ovarian carcinoma: Thus, to investigate the anti-cancer effect of OXY as a PI3K/AKT signaling blocker and assess the possibility of its use in clinical practice, we conducted an in vitro study on ovarian cancer cell lines (SKOV3 and TOV21G).